The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,404.00
Bid: 12,416.00
Ask: 12,418.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.016%)
Open: 12,330.00
High: 0.00
Low: 0.00
Prev. Close: 12,404.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: BP Up As Alaskan Sale Paves Way For Payouts

Wed, 28th Aug 2019 10:37

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------BP, up 2.2%. After the London market close on Tuesday, the oil and gas company said it has agreed to sell all of its Alaskan operations to Hilcorp Alaska for USD5.6 billion. The sale will include BP's entire upstream and midstream business in the state, including BP Exploration (Alaska), which owns all of BP's upstream oil and gas interests in the region, and BP Pipelines (Alaska)'s interest in the Trans Alaska Pipeline System. Hilcorp Alaska is an affiliate of Houston-headquartered Hilcorp Energy. Of the USD5.6 billion consideration, USD4.0 billion is payable "near-term" and USD1.6 billion through an earnout thereafter. Subject to state and federal regulatory approval, the sale is expected to complete in 2020. Analysts said they expect to see a dividend increase from BP as a result.----------AstraZeneca, up 1.1%. The drugmaker posted positive results from its phase three trial of Breztri Aerosphere and said Fasenra has been granted orphan drug designation in the US. The phase 3 trial of Breztri Aerosphere in COPD met its primary endpoint, demonstrating "a statistically-significant reduction in the rate of moderate or severe exacerbations" when compared to the dual-combination therapies Bevespi Aerosphere and PT009. Breztri Aerosphere is a combination of budesonide, glycopyrronium, and formoterol fumarate. The study found a statistically significant reduction in the rate of severe to moderate exacerbations both at the standard budesonide dose and at a half dose of budesonide versus dual-combination therapies. In addition, Astra announced that the US Food & Drug Administration has granted Fasenra orphan drug designation as a treatment for eosinophilic oesophagitis.----------FTSE 250 - WINNERS----------Greggs, up 3.6%. UBS raised the vegan sausage roll maker to Buy from Neutral. ----------Diploma, up 2.0%. The technical products and services firm said it is trading in line with expectations and forecasts double-digit full-year revenue growth. For the financial year ending September 30, the company expects a rise in revenue of 13% to GBP548.2 million from GBP485.1 million reported in financial 2018. Revenue is expected to grow 5% on an underlying basis, while currency exchange and recent acquisitions are forecast to improve revenue by 2% and 6% respectively. Chief Executive Johnny Thomson said: "Diploma continues to have a good year. We are on track to deliver strong underlying growth with positive contributions from acquisitions and modest margin progression."----------FTSE 250 - LOSERS----------James Fisher & Sons, down 2.5%. The marine services provider warned that its Marine Support unit had a slower start to the year due to a weak market in South Africa and provisions for contracts and doubtful debt. The company recorded a decline in pretax profit for the six months to the end of June to GBP20.9 million from GBP21.5 million a year earlier. Revenue meanwhile increased by 10% to GBP260.5 million, thanks to a strong performance from the Offshore Oil and Tankships divisions. At constant currency and excluding acquisitions, revenue grew by 4%. "The phasing of projects has made the year more weighted to the second half, which will also begin to benefit from the investment committed to in the first half. The group remains well placed to deliver an improved financial performance in the year and to continue to provide future value to its shareholders," said Chief Executive Nick Henry.----------OTHER MAIN MARKET AND AIM - WINNERS----------Wey Education, up 14%. The online school & sixth form college operator said revenue will exceed market expectations for its current financial year due to strong trading. Revenue for the firm's year, which will end on Saturday, is set to be more than GBP6.0 million, which would be 43% ahead of its GBP4.2 million revenue the year before, and "well ahead of market expectations". Wey said the higher revenue has allowed it to raise marketing spend in order to meet its financial 2020 revenue expectations. Adjusted profit for the current financial 2019 year will be in line with market expectations, it said.----------OTHER MAIN MARKET AND AIM - LOSERS----------OptiBiotix, down 30%. The life sciences firm reported a widened in loss in the first half of its financial year, as the company said it continues its transition from a research & development firm into a commercial business. In the six months that ended May 31, OptiBiotix's pretax loss widened to GBP1.3 million from GBP1.2 million the year before. Revenue remained insignificant, though it almost doubled to GBP148,818 from GBP80,560. The majority of the company's revenue in the half was generated from LP-LDL with GoFigure online and export sales contributing the rest. SlimBiome revenue contributed "very little". OptiBiotix said its administrative expenses were flat year on year at GBP1.0 million. Looking forward, OptiBiotix said it expects revenue to grow further in its financial second half, as a "large corporate partner" launches products in the first quarter of 2020.----------President Energy, down 16%. The oil and gas company will shift focus from oil sales to gas sales in a move to retain profitability in Argentina following the local government's recent attempt to control fuel prices in the country. The Argentinian government has issued a 90 day decree to limit fuel prices for customers. "The Decree fixed, solely for oil producers, the base values for the peso/dollar exchange rate and the reference price of Brent used in the calculation of the oil price receivable," explained President Energy. As a result, the company has decided to defer its drilling campaign scheduled for this year and instead expand its existing gas projects. President said the decree does not affect gas prices. President has re-scheduled its well drilling campaign for the first quarter of 2020, with an emphasis on new gas wells.----------Thomas Cook Group, down 15%. The holiday operator agreed a "significant" new capital investment with its largest shareholder Fosun Tourism Group, core lending banks, and a majority of 2022 and 2023 senior noteholders. Thomas Cook's shareholders will be "significantly diluted" by this funding plans, which involve the conversion of debt to equity. The holiday operator said Fosun will contribute GBP450 million of new money to the company and will buy at least 75% of the equity of its Tour Operator unit, plus 25% of its Airline operations. Thomas Cook said its current intention is to maintain the company's London listing but the proposed recapitalisation could result in Thomas Cook cancelling its listing. The company also stressed the recapitalisation remains subject to a number of factors, including credit and investment approvals and the allocation of risk between Fosun and the company's creditors. ----------

More News
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.